TBCRC 030: A phase II study of preoperative cisplatin vs. paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker.
暂无分享，去创建一个
C. Perou | E. Winer | L. Trippa | L. Carey | A. Wolff | N. Tung | A. Richardson | P. Marcom | T. Traina | V. Stearns | C. Falkson | E. Winer | V. Abramson | K. Timms | K. Miller | E. Mayer | I. Krop | R. Jankowitz | J. Specht | M. Rimawi | Z. Tan-Wasielewski | C. Perou | K. Componeschi | L. Carey | Jennifer M. Specht | Kathy D. Miller | Andrea L. Richardson